A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-7072 Following Oral Administration
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2016
At a glance
- Drugs KBP 7072 (Primary)
- Indications Bacterial infections
- Focus Adverse reactions
- Sponsors KBP Biosciences
- 30 Oct 2016 Results assessing safety, tolerability and pharmacokinetics of KBP-7072 presented at the IDWeek 2016.
- 28 Dec 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 12 Jun 2015 New trial record